Compounds > n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4--fluoresceinthiocarbamoyl)-l-lysine-trihydrate

n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4--fluoresceinthiocarbamoyl)-l-lysine-trihydrate and Arthritis--Rheumatoid

n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4--fluoresceinthiocarbamoyl)-l-lysine-trihydrate has been researched along with Arthritis--Rheumatoid* in 1 studies

Other Studies

1 other study(ies) available for n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4--fluoresceinthiocarbamoyl)-l-lysine-trihydrate and Arthritis--Rheumatoid

Article	Year
New gamma-fluoromethotrexates modified in the pteridine ring: synthesis and in vitro immunosuppressive activity. European journal of medicinal chemistry, 2000, Volume: 35, Issue:5 Our continuing program to develop new antifolate drugs useful against rheumatoid arthritis led us to modify the pteridine ring of gamma-fluoromethotrexate. Pyrrolopyrimidine derivatives 1e and 1t were found to exhibit potent suppressive effects on the responses of both T and B cells to mitogens, although tetrahydropyridopyrimidine derivatives 2e and 2t and quinazoline derivatives 3e, 3t and 4e showed very weak suppressive activities. Thus, conversion of the pteridine ring of gamma-fluoromethotrexate to a pyrrolopyrimidine ring led to a new potential antirheumatic compound. Topics: Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Folic Acid Antagonists; Glutamic Acid; Humans; Immunosuppressive Agents; Methotrexate; Mitogens; Molecular Structure; Pteridines; Pyrimidines; T-Lymphocytes	2000

Article

Year

New gamma-fluoromethotrexates modified in the pteridine ring: synthesis and in vitro immunosuppressive activity.

European journal of medicinal chemistry, 2000, Volume: 35, Issue:5

Our continuing program to develop new antifolate drugs useful against rheumatoid arthritis led us to modify the pteridine ring of gamma-fluoromethotrexate. Pyrrolopyrimidine derivatives 1e and 1t were found to exhibit potent suppressive effects on the responses of both T and B cells to mitogens, although tetrahydropyridopyrimidine derivatives 2e and 2t and quinazoline derivatives 3e, 3t and 4e showed very weak suppressive activities. Thus, conversion of the pteridine ring of gamma-fluoromethotrexate to a pyrrolopyrimidine ring led to a new potential antirheumatic compound.

Topics: Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Folic Acid Antagonists; Glutamic Acid; Humans; Immunosuppressive Agents; Methotrexate; Mitogens; Molecular Structure; Pteridines; Pyrimidines; T-Lymphocytes

2000